DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United Kingdom
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
HIK logo

Hikma Pharmaceuticals PLC Stock Price

LSE:HIK Community·UK£3.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 77 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

HIK Share Price Performance

UK£16.00
-0.33 (-2.02%)
​
UK£19.70
Fair Value
UK£16.00
-0.33 (-2.02%)
18.8% undervalued intrinsic discount
UK£19.70
Fair Value
Price UK£16.00
AnalystConsensusTarget UK£19.70
AnalystLowTarget UK£17.00
AnalystHighTarget UK£24.79
Fri, 4 Sep 26
Fair ValueUK£19.70
Share Pricen/a

HIK Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value UK£19.7 18.8% undervalued intrinsic discount

Expanded US Market Access Will Drive Momentum Amid Regulatory Headwinds

1users have liked this narrative
0users have commented on this narrative
42users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value UK£17 5.9% undervalued intrinsic discount

Injectable Expansion And MENA Scale Will Shape A Cautious Yet Steady Outlook

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value UK£24.79 35.5% undervalued intrinsic discount

Rising CMO And Injectable Pipelines Will Support A Stronger Long Term Outlook

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
HIK logo
Hikma Pharmaceuticals
18.8% undervalued intrinsic discount

Expanded US Market Access Will Drive Momentum Amid Regulatory Headwinds

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 4 Sep
Read Narrative
HIK logo
Hikma Pharmaceuticals
5.9% undervalued intrinsic discount
Updated

Injectable Expansion And MENA Scale Will Shape A Cautious Yet Steady Outlook

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 18 Sep
Read Narrative
HIK logo
Hikma Pharmaceuticals
35.5% undervalued intrinsic discount

Rising CMO And Injectable Pipelines Will Support A Stronger Long Term Outlook

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 14 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
HIK logo

HIK: Execution Reset And Pipeline Progress Will Shape Fairly Valued Outlook

Fair Value: UK£17 5.9% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
HIK logo

HIK: Margin Resilience And Buybacks Will Support Future Re Rating

Fair Value: UK£19.7 18.8% undervalued intrinsic discount
42 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
HIK logo

HIK: US Manufacturing Expansion Will Support Future Earnings Rebound

Fair Value: UK£24.79 35.5% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Very undervalued with adequate balance sheet and pays a dividend.

2 Risks
5 Rewards
View Full Analysis

Hikma Pharmaceuticals PLC Key Details

US$3.4b

Revenue

US$1.9b

Cost of Revenue

US$1.5b

Gross Profit

US$1.1b

Other Expenses

US$387.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
1.84
44.05%
11.32%
73.7%
View Full Analysis

About HIK

Founded
1978
Employees
9500
CEO
Said Darwazah
WebsiteView website
www.hikma.com

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

Recent HIK News & Updates

User avatar
Narrative Update • Sep 18

HIK: Execution Reset And Pipeline Progress Will Shape Fairly Valued Outlook

Analysts have raised their fair value estimate for Hikma Pharmaceuticals from £13.61 to £17.00. This reflects higher price targets that reference an end to recent execution shortfalls and earnings downgrades, alongside updated assumptions for margins, growth and future P/E multiples.
User avatar
Narrative Update • Sep 04

HIK: Margin Resilience And Buybacks Will Support Future Re Rating

Analysts have lifted their fair value estimate for Hikma Pharmaceuticals from £18.74 to £19.70, pointing to higher Street price targets in the £1,870 to £2,100 range as they refine assumptions on the discount rate, margin resilience and future P/E. Analyst Commentary Recent research on Hikma Pharmaceuticals shows a clear tilt toward optimism on execution and valuation, with several price targets now clustered well above the latest fair value estimate.

Recent updates

No updates

Hikma Pharmaceuticals PLC Competitors

HCM logo

HUTCHMED (China)

Symbol: AIM:HCM
Market cap: UK£1.8b
ONT logo

Oxford Nanopore Technologies

Symbol: LSE:ONT
Market cap: UK£1.7b
GNS logo

Genus

Symbol: LSE:GNS
Market cap: UK£1.4b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide